More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.07B
EPS
-0.04
P/E ratio
--
Price to sales
5.7
Dividend yield
--
Beta
0.822819
Previous close
$16.70
Today's open
$16.83
Day's range
$16.39 - $16.94
52 week range
$5.25 - $16.98
show more
CEO
John Shannon
Employees
435
Headquarters
Chicago, IL
Exchange
Nasdaq Global Select
Shares outstanding
182700038
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Top 3 Health Care Stocks That May Collapse This Month
As of Nov. 16, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Benzinga • Nov 16, 2026

Xeris Biopharma: Time For A Pause
Xeris Biopharma Holdings has more than doubled since my March buy rating, driven by strong Q3 results and raised guidance. XERS posted a surprise GAAP profit of $0.06 per share, $11.3M net income, and 44% revenue growth to $107.2M, exceeding expectations. Gross margins improved to 88%, and Xeris eliminated $34M of convertible notes, reducing annual interest by $3M and strengthening its balance sheet.
Seeking Alpha • Nov 12, 2026

Xeris Biopharma Q3 Earnings Call Highlights
Xeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.
MarketBeat • Nov 6, 2026

Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Cristi Barnett - Vice President of Investor Relations John Shannon - Chairman & CEO Steven Pieper - Chief Financial Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Hello, everyone.
Seeking Alpha • Nov 6, 2026

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced its financial results and business highlights for the third quarter ended September 30, 2026. “As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve tha.
Business Wire • Nov 5, 2026

Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates
Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
Zacks Investment Research • Nov 5, 2026

Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 5, 2026

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced the appointment of Menassie M. Taddese to its Board of Directors, effective today. Taddese will also serve on the Board's Audit Committee. “We are delighted to welcome Menassie to the Xeris Board,” said John Shannon, Chairman a.
Business Wire • Nov 2, 2026

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call.
Business Wire • Oct 22, 2026

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.
Business Wire • Oct 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Xeris Biopharma Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.